JAZZ vs OMER
JAZZ: Jazz Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for patients with complex sleep disorders and challenging oncology conditions. OMER: A clinical-stage biotech company commercializing complement-pathway inhibitors for rare hematologic and immune diseases, with FDA-approved YARTEMLA for stem cell transplant complications and a $240M asset sale of its lead MASP-3 program to Novo Nordisk.
Side-by-side fundamentals
| Metric | JAZZ | OMER | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $256.65 | $13.15 | |
| Market cap as of 2026-08-08 | $16.1B | $952M | |
| P/E as of 2026-08-08 | 17.71 | 11.10 | OMER lower |
| PEG as of 2026-08-08 | 65.11 | n/a | |
| Net margin as of 2026-08-08 | +20.4% | +566.7% | OMER higher |
| Gross margin as of 2026-08-08 | +88.4% | +94.1% | OMER higher |
| Operating margin as of 2026-08-08 | +19.5% | -176.1% | JAZZ higher |
| ROE as of 2026-08-08 | +21.4% | +107.5% | OMER higher |
| ROA as of 2026-08-08 | +8.2% | +34.5% | OMER higher |
| Debt / equity as of 2026-08-08 | 0.91 | 21.55 | JAZZ lower |
| Revenue growth (YoY) as of 2026-08-08 | +12.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +5.3% | +4.4% | JAZZ higher |
| Beta as of 2026-08-08 | 0.37 | 2.55 | |
| 1-year return as of 2026-08-06 close | +142.3% | +240.7% | OMER higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.